Featured Editorial

  1. Geopolitical Risk Is Reshaping Clinical Trial Supply Chains 5/12/2026

    Rising geopolitical risk and fuel volatility are breaking clinical supply assumptions, forcing new strategies to protect trial timelines, patient access, and product integrity.

  2. How Real-World, Real-Time, And Synthetic Data Are Revolutionizing Clinical Trial Supply Chains 5/11/2026

    Real-time, real-world, and synthetic data are turning trial supply chains into proactive systems that reduce waste, improve forecasting, and ensure patients get therapies faster.

  3. The Atlantic Divide: Forcing FDA Demographics Onto European Supply Chains 5/8/2026

    FDA demographic mandates can upend global trial supply, stranding inventory, driving panic packaging, and creating hidden bias that undermines study execution.

  4. Expanding Clinical Trials In Africa Without Disruption 5/7/2026

    A structured five-layer framework helps sponsors expand clinical trials in Africa with clarity, reducing risk, strengthening governance, and improving ROI.

  5. Bridging Clinical Operations And Supply Chain: Aligning Execution In High-Stakes Trials 5/7/2026

    Small disconnects between clinical ops and supply chain can derail complex trials. Strong alignment keeps forecasts accurate, supply on track, and patients supported.

  6. At The Point Of Review: How Clinical Shipments Are Evaluated In Practice 5/6/2026

    At review, clinical shipments become a single consolidated record. Delays arise when relationships between product identity, classification, and documentation are unclear.

  7. The cGMP Reality Of Clinical Supply For Advanced Therapies 5/5/2026

    Breakthrough therapies fail without cGMP‑ready supply. In cell and gene therapies, quality systems, timing, documentation and logistics dictate patient access.

  8. How Exit Strategy Should Shape Clinical Trial Supply Planning 5/5/2026

    Clinical trial supply risks often surface at closeout. Planning for early termination and inventory unwind from the start helps avoid waste, delays, and costly write-offs.

  9. This Assumption Will Break Your Clinical Trial 5/4/2026

    Clinical trial supply chains are built for stability, but permanent disruption is breaking RTSM assumptions and forcing a redesign of planning, inventory, and logistics architecture.

  10. When Clinical Supply Fails, Small Biotech Trials Stall 5/1/2026

    Small biotech trials succeed or fail on clinical supply discipline, where forecasting, comparator sourcing, and global execution determine whether patients stay on treatment.